Apoptosis: A target for potentiation of UV-induced IL-1Ra synthesis by IVIg

Immunology Letters

Volumn 110, Issue 1, 2007, Pages 36-41

  Craciun, Ligia I ^a   DiGiambattista, Mario ^b   Laub, Ruth ^b   Goldman, Michel ^a   Dupont, Etienne ^a  

^a ERASME HOSPITAL   (Belgium)

^b Research and Development DCF CAF   (Belgium)

Author keywords

Apoptosis; IL 1Ra; IVIg; Monocyte macrophages; UV light

Indexed keywords

FC RECEPTOR; IMMUNOGLOBULIN; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; LIPOCORTIN 5; MULTIGAM; SANDOGLOBULINE; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; ASSAY; COCULTURE; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACTIVITY; DRUG MECHANISM; DRUG POTENCY; HUMAN; HUMAN CELL; IN VITRO STUDY; INCUBATION TEMPERATURE; INCUBATION TIME; LYMPHOCYTE CULTURE; NORMAL HUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; ULTRAVIOLET RADIATION;

ANIMALS; APOPTOSIS; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; ULTRAVIOLET RAYS;

EID: 34247626921     PISSN: 01652478     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.imlet.2007.02.010     Document Type: Article

References (40)

1. Dinarello C.A. Interleukin-1, interleukin-1 receptors and interleukin-1 receptor antagonist. Int Rev Immunol 16 (1998) 457-499
2. Arend W.P., Malyak M., Guthridge C.J., and Gabay C. Interleukin-1 receptor antagonist: role in biology. Annu Rev Immunol 16 (1998) 27-55
3. Dinarello C.A. Therapeutic strategies to reduce IL-1 activity in treating local and systemic inflammation. Curr Opin Pharmacol 4 (2004) 378-385
4. Arend W.P., and Dayer J.M. Cytokines and cytokine inhibitors or antagonists in rheumatoid arthritis. Arthritis Rheum 33 (1990) 305-315
5. Moosig F., Zeuner R., Renk C., and Schroder J.O. IL-1Ra in refractory systemic lupus erythematosus. Lupus 13 (2004) 605-606
6. McCarthy Jr. P.L., Abhyankar S., Neben S., Newman G., Sieff C., Thompson R.C., et al. Inhibition of interleukin-1 by an interleukin-1 receptor antagonist prevents graft-versus-host disease. Blood 78 (1991) 1915-1918
7. Sandberg J.O., Eizirik D.L., Sandler S., Tracey D.E., and Andersson A. Treatment with an interleukin-1 receptor antagonist protein prolongs mouse islet allograft survival. Diabetes 42 (1993) 1845-1851
8. Yamada J., Zhu S.N., Streilein J., and Dana M.R. Interleukin-1 receptor antagonist therapy and induction of anterior chamber-associated immune deviation-type tolerance after corneal transplantation. Invest Ophthalmol Vis Sci 41 (2000) 4203-4208
9. Saadi S., Takahashi T., Holzknecht R.A., and Platt J.L. Pathways to acute humoral rejection. Am J Pathol 164 (2004) 1073-1080
10. Yang H., Tuzun E., Alagappan D., Yu X., Scott B.G., Ischenko A., et al. IL-1 receptor antagonist-mediated therapeutic effect in murine myasthenia gravis is associated with suppressed serum proinflammatory cytokines, C3 and anti-acetylcholine receptor IgG1. J Immunol 175 (2005) 2018-2020
11. Hawkins P.N., Lachmann H.J., and McDermott M.F. Interleukin-1-receptor antagonist in the Muckle-Wells syndrome. New Engl J Med 348 (2003) 2583-2584
12. Hoffman H.M., Rosengren S., Boyle D.L., Cho J.Y., Nayar J., Mueller J.L., et al. Prevention of cold-associated acute inflammation in familial cold autoinflammatory syndrome by interleukin-1 receptor antagonist. Lancet 364 (2004) 1779-1785
13. Conti F., Breton S., Batteux F., Furlan V., Houssin D., Weill B., et al. Defective interleukin-1 receptor antagonist production is associated with resistance of acute liver graft rejection to steroid therapy. Am J Pathol 157 (2000) 1685-1692
14. Janson R.W., Hance K.R., and Arend W.P. Production of IL-1 receptor antagonist by human in vitro-derived macrophages. Effects of lipopolysaccharide and granulocyte-macrophage colony-stimulating factor. J Immunol 147 (1991) 4218-4223
15. Roux-Lombard P., Modoux C., and Dayer J.M. Production of interleukin-1 (IL-1) and a specific IL-1 inhibitor during human monocyte-macrophage differentiation: influence of GM-CSF. Cytokine 1 (1989) 45-51
16. de Souza V.R., Carreno M.P., Kaveri S.V., Ledur A., Sadeghi H., Cavaillon J.M., et al. Selective induction of interleukin-1 receptor antagonist and interleukin-8 in human monocytes by normal polyspecific IgG (intravenous immunoglobulin). Eur J Immunol 25 (1995) 1267-1273
17. Coopamah M.D., Freedman J., and Semple J.W. Anti-D initially stimulates an Fc-dependent leukocyte oxidative burst and subsequently suppresses erythrophagocytosis via interleukin-1 receptor antagonist. Blood 102 (2003) 2862-2867
18. Aukrust P., Froland S.S., Liabakk N.B., Muller F., Nordoy I., Haug C., et al. Release of cytokines, soluble cytokine receptors, and interleukin-1 receptor antagonist after intravenous immunoglobulin administration in vivo. Blood 84 (1994) 2136-2143
19. Schwaighofer H., Oberhuber G., Hebart H., Einsele H., Herold M., Nachbaur D., et al. Endogenous interleukin 1 receptor antagonist during human bone marrow transplantation: increased levels during graft-versus-host disease, during infectious complications, and after immunoglobulin therapy. Transplantation 63 (1997) 52-56
20. Gullestad L., Aass H., Fjeld J.G., Wikeby L., Andreassen A.K., Ihlen H., et al. Immunomodulating therapy with intravenous immunoglobulin in patients with chronic heart failure. Circulation 103 2 (2001) 220-225
21. Crow A.R., Song S., Semple J.W., Freedman J., and Lazarus A.H. A role for IL-1 receptor antagonist or other cytokines in the acute therapeutic effects of IVIg?. Blood 109 (2007) 155-158
22. Kazatchkine M.D., and Kaveri S.V. Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. New Engl J Med 345 (2001) 747-755
23. Craciun L.I., Stordeur P., Schandene L., Duvillier H., Bron D., Lambermont M., et al. Increased production of interleukin 10 and interleukin-1 receptor antagonist after extracorporeal photochemotherapy in chronic graft-versus-host disease. Transplantation 74 (2002) 995-1000
24. Craciun L.I., Digiambattista M., Schandene L., Laub R., Goldman M., and Dupont E. Anti-inflammatory effects of UV-irradiated lymphocytes: induction of IL-1Ra upon phagocytosis by monocytes/macrophages. Clin Immunol 114 (2005) 320-326
25. Fadok V.A., Bratton D.L., and Henson P.M. Phagocyte receptors for apoptotic cells: recognition, uptake and consequences. J Clin Invest 108 (2001) 957-962
26. Savill J., Dransfield I., Gregory C., and Haslett C. A blast from the past: clearance of apoptotic cells regulates immune responses. Nat Rev Immunol 2 (2002) 965-975
27. Voll R.E., Hermann M., Roth E.A., Stach C., Kalden J.R., and Girkontaite I. Immunosuppressive effects of apoptotic cells. Nature 390 (1997) 350-351
28. Prasad N.K., Papoff G., Zeuner A., Bonnin E., Kazatchkine M.D., Ruberti G., et al. Therapeutic preparations of normal polyspecific IgG (IVIg) induce apoptosis in human lymphocytes and monocytes: a novel mechanism of action of IVIg involving the Fas apoptotic pathway. J Immunol 161 (1998) 3781-3790
29. Altznauer F., von Gunten S., Spath P., and Simon H.U. Concurrent presence of agonistic and antagonistic anti-CD95 autoantibodies in intravenous Ig preparations. J Allergy Clin Immunol 112 (2003) 1185-1190
30. Stordeur P., Poulin L., Craciun L., Zhou L., Schandene L., de Lavareille A., et al. Cytokine mRNA quantification by real time PCR. J Immunol Methods 259 (2002) 55-64
31. Svenson M., Hansen M.B., Ross C., Diamant M., Rieneck K., Nielsen H., et al. Antibody to granulocyte-macrophage colony-stimulating factor is a dominant anti-cytokine activity in human IgG preparations. Blood 91 (1998) 2054-2061
32. Blazar B.R., Taylor P.A., Smith S., and Vallera D.A. Interleukin-10 administration decreases survival in murine recipients of major histocompatibility complex disparate donor bone marrow grafts. Blood 85 (1995) 842-851
33. Wissing K.M., Morelon E., Legendre L., De Pauw L., LeBeaut A., Grint P., et al. A pilot trial of recombinant human interleukin-10 in kidney transplant recipients receiving OKT3 induction therapy. Transplantation 64 (1997) 999-1006
34. Nimmerjahn F., and Ravetch J.V. The antiinflammatory activity of IgG: the intravenous IgG paradox. J Exp Med 204 1 (2007) 11-15
35. Morell A. Pharmacokinetics of intravenous immunoglobulin preparations. In: Lee M.L., and Strand V. (Eds). Intravenous immunoglobulins in clinical practice (1997), Marcel Dekker, New York 1-22
36. Edelson R., Berger C., Gasparro F., Jegasothy B., Heald P., Wintroub B., et al. Treatment of cutaneous T-cell lymphoma by extracorporeal photochemotherapy. Preliminary results. New Engl J Med 316 (1987) 297-303
37. Russo G.G., and Mullen C. Cutaneous and non-cutaneous disorders treated with extracorporeal photopheresis. Int J Dermatol 40 (2001) 89-100
38. Greinix H.T., Volc-Platzer B., Rabitsch W., Gmeinhart B., Guevara-Pineda C., Kalhs P., et al. Extracorporeal photochemotherapy in the treatment of severe acute and chronic graft-versus-host diseases. Blood 92 (1998) 3098-3104
39. Glotz D., Antoine C., Julia P., Suberbielle-Boissel C., Bouldjeltia S., Fraoui L., et al. Desensitization and subsequent kidney transplantation of patients using intravenous immunoglobulins (IVIg). Am J Transplant 2 (2002) 758-760
40. Donald Y., Leung M., and Schlievert M. The immunopathogenesis and management of Kawasaki syndrome. Arthritis Rheum 41 (1998) 1538-1547